These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 25588353

  • 21. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
    Kovács N, Aschermann Z, Ács P, Bosnyák E, Deli G, Janszky J, Komoly S.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):245-50. PubMed ID: 25509365
    [Abstract] [Full Text] [Related]

  • 22. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
    Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, LCIG Horizon Study Group.
    Lancet Neurol; 2014 Feb 30; 13(2):141-9. PubMed ID: 24361112
    [Abstract] [Full Text] [Related]

  • 23. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
    Othman AA, Rosebraugh M, Chatamra K, Locke C, Dutta S.
    J Parkinsons Dis; 2017 Feb 30; 7(2):275-278. PubMed ID: 28211816
    [Abstract] [Full Text] [Related]

  • 24. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
    Udd M, Lyytinen J, Eerola-Rautio J, Kenttämies A, Lindström O, Kylänpää L, Pekkonen E.
    Brain Behav; 2017 Jul 30; 7(7):e00737. PubMed ID: 28729942
    [Abstract] [Full Text] [Related]

  • 25. Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson's disease: A large single-center study.
    Blaise AS, Baille G, Carrière N, Devos D, Dujardin K, Grolez G, Kreisler A, Kyheng M, Moreau C, Mutez E, Seguy D, Defebvre L.
    Rev Neurol (Paris); 2020 May 30; 176(4):268-276. PubMed ID: 31668287
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
    Zibetti M, Rizzone M, Merola A, Angrisano S, Rizzi L, Montanaro E, Cicolin A, Lopiano L.
    Acta Neurol Scand; 2013 May 30; 127(5):e28-32. PubMed ID: 23311399
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.
    Buongiorno M, Antonelli F, Cámara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, Calopa M, Pascual-Sedano B, Campolongo A, Valldeoriola F, Tolosa E, Kulisevsky J, Martí MJ.
    Parkinsonism Relat Disord; 2015 Aug 30; 21(8):871-6. PubMed ID: 26003410
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
    Regidor I, Santos-García D, Catalán MIJ, Puente V, Valldeoriola F, Grandas F, Mir P, Parra JC, Arbelo JM.
    J Parkinsons Dis; 2019 Aug 30; 9(1):173-182. PubMed ID: 30562907
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
    Othman AA, Dutta S.
    Br J Clin Pharmacol; 2014 Jul 30; 78(1):94-105. PubMed ID: 24433449
    [Abstract] [Full Text] [Related]

  • 34. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
    Waters CH, Nausieda P, Dzyak L, Spiegel J, Rudzinska M, Silver DE, Tsurkalenko ES, Kell S, Hsu A, Khanna S, Gupta S.
    CNS Drugs; 2015 Apr 30; 29(4):341-50. PubMed ID: 25895021
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J, Sail K, Baj R, Jalundhwala YJ, Marshall TS, Konwea H, Chaudhuri KR.
    J Med Econ; 2017 Nov 30; 20(11):1207-1215. PubMed ID: 28895769
    [Abstract] [Full Text] [Related]

  • 37. Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients.
    Sücüllü Karadağ Y, Saltoğlu T, Erdoğan Küçükdağli F, Öztürk Ö, Köseoğlu HT, Altiparmak E.
    Turk J Med Sci; 2021 Feb 26; 51(1):84-89. PubMed ID: 32718129
    [Abstract] [Full Text] [Related]

  • 38. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
    Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P, GLORIA study co-investigators.
    Parkinsonism Relat Disord; 2017 Dec 26; 45():13-20. PubMed ID: 29037498
    [Abstract] [Full Text] [Related]

  • 39. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
    Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S.
    Parkinsonism Relat Disord; 2014 Dec 26; 20(12):1335-40. PubMed ID: 25306200
    [Abstract] [Full Text] [Related]

  • 40. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
    LeWitt PA, Huff FJ, Hauser RA, Chen D, Lissin D, Zomorodi K, Cundy KC.
    Mov Disord; 2014 Jan 26; 29(1):75-82. PubMed ID: 24339234
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.